Skip to main content
Equibles
RPRX logo

RPRX · Royalty Pharma plc · Webcasts, Transcripts & Audio

Track RPRX — free

Use RPRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RPRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.17 -0.46 (-0.80%)
Russell 1000 member Rebalance outlook locked
Market Cap
$33.47B
Shares
575.00M
Volume · Oct 1 3.25M Avg daily vol (3M) 2.93M

Royalty Pharma plc Webcasts

Earnings calls, investor updates, investor days and conferences for Royalty Pharma plc (RPRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼2.1% $573.46M $142.65M '22 Q3 22-11-08 ▼1.7% $565.75M −$456.08M '22 Q4 23-01-09 ▲21.7% $683.97M $340.75M '23 Q1 23-05-09 ▲0.4% $538.20M $227.62M '23 Q2 23-08-08 ▼6.5% $536.31M $72.11M '23 Q3 23-11-08 ▲5.4% $596.07M $494.34M '23 Q4 24-02-15 ▼17% $567.98M $4.78M '24 Q1 24-05-09 ▼0.2% $537.27M $102.00M '24 Q2 24-08-08 ▲5.3% $564.69M $543.99M '24 Q3 24-11-06 ▼0.4% $593.64M $208.21M '24 Q4 25-01-10 ▲0% $568.25M $239.35M '25 Q1 25-05-08 ▲7.7% $578.66M $32.18M '25 Q2 25-08-06 ▲7.9% $609.29M $288.22M '25 Q3 25-11-05 ▲4.8% $621.99M $211.21M '25 Q4 26-02-11 ▲11% $630.58M $294.69M '26 Q1 26-05-06 LATEST ▲16.5% $674.14M $17.88M '26 Q2 26-08-05
Conference
Investor event
2026-09-23
Royalty Pharma plc (RPRX) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-23
Royalty Pharma plc (RPRX) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Royalty Pharma plc (RPRX) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
Confident tone Portfolio Receipt Growth & Guidance Raise Chloramatug (TTR Amyloidosis) Acquisition China Market Opportunity
Revenue
$674.14M
▲ 16.5% YoY
Diluted EPS
$0.04
▼ 42.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Royalty Pharma plc (RPRX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Confident tone R&D Co-Funding Portfolio Receipts Growth Clinical and Regulatory Updates
Revenue
$630.58M
▲ 11% YoY
Diluted EPS
$0.67
▲ 21.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-03
Royalty Pharma plc (RPRX) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-11
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
Confident tone Financial performance and growth Transaction pipeline and synthetic royalties Capital deployment and shareholder returns
Revenue
$621.99M*
▲ 4.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2025-12-03
Royalty Pharma plc (RPRX) December 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-05
Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript
Confident tone LP(a) clinical program (olpacican/alpacoran) Portfolio receipts and top-line growth Returns on capital
Revenue
$609.29M
▲ 7.9% YoY
Diluted EPS
$0.67
▼ 44.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript
Confident tone Portfolio Receipts growth and guidance raise Clinical and product news across portfolio External manager acquisition / internalization
Revenue
$578.66M
▲ 7.7% YoY
Diluted EPS
$0.07
▼ 69.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript
Confident tone Financial Performance and Guidance Litifilimab / Biogen Partnership Capital Allocation and Share Repurchases
Revenue
$568.25M
▲ 0% YoY
Diluted EPS
$0.55
▲ 5400% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript
Confident tone Portfolio Receipts and financial performance Internalization of external manager Capital deployment and share repurchases
Revenue
$593.64M*
▼ 0.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Transcript
Confident tone Syndax / Niktimvo Deal Portfolio Receipts Growth Portfolio Products and Approvals
Revenue
$564.69M
▲ 5.3% YoY
Diluted EPS
$1.21
▲ 656.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript
Confident tone Portfolio receipts growth and raised guidance Voranigo acquisition and commercial launch Repeat business and partnership relationships
Revenue
$537.27M
▼ 0.2% YoY
Diluted EPS
$0.23
▼ 54% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Royalty Pharma plc (RPRX) Q1 2024 Earnings Call Transcript
Confident tone Frexalimab acquisition Development-stage pipeline Financial results and guidance
Revenue
$567.98M
▼ 17% YoY
Diluted EPS
$0.01
▼ 98.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Royalty Pharma plc (RPRX) Q4 2023 Earnings Call Transcript
Confident tone Portfolio growth and acquisitions Financial performance and 2024 guidance Tysabri biosimilar exposure
Revenue
$596.07M*
▲ 5.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Royalty Pharma plc (RPRX) Q3 2023 Earnings Call Transcript
Revenue
$536.31M
▼ 6.5% YoY
Diluted EPS
$0.16
▼ 50% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Royalty Pharma plc (RPRX) Q2 2023 Earnings Call Transcript
Revenue
$538.20M
▲ 0.4% YoY
Diluted EPS
$0.50
▼ 28.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Royalty Pharma plc (RPRX) Q1 2023 Earnings Call Transcript
Revenue
$683.97M
▲ 21.7% YoY
Diluted EPS
$0.76
▲ 533.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Royalty Pharma plc (RPRX) Q4 2022 Earnings Call Transcript
Revenue
$565.75M*
▼ 1.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Royalty Pharma plc (RPRX) Q3 2022 Earnings Call Transcript
Revenue
$573.46M
▼ 2.1% YoY
Diluted EPS
$0.32
▲ 33.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Royalty Pharma plc (RPRX) Q2 2022 Earnings Call Transcript
Revenue
$535.96M
▼ 3.4% YoY
Diluted EPS
$0.70
▼ 35.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Royalty Pharma plc (RPRX) Q1 2022 Earnings Call Transcript
Revenue
$562.05M
▼ 1.9% YoY
Diluted EPS
$0.12
▼ 33.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Royalty Pharma plc (RPRX) Q4 2021 Earnings Call Transcript
Revenue
$575.70M*
▲ 0.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Royalty Pharma plc (RPRX) Q3 2021 Earnings Call Transcript
Revenue
$585.77M
▲ 8.8% YoY
Diluted EPS
$0.24
▼ 69.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Royalty Pharma plc (RPRX) Q2 2021 Earnings Call Transcript
Revenue
$554.96M
▲ 8.6% YoY
Diluted EPS
$1.08
▲ 1100% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Royalty Pharma plc (RPRX) Q1 2021 Earnings Call Transcript
Revenue
$573.03M
▲ 14.4% YoY
Diluted EPS
$0.18
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Royalty Pharma plc (RPRX) Q4 2020 Earnings Call Transcript
Revenue
$572.14M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Royalty Pharma plc (RPRX) Q3 2020 Earnings Call Transcript
Revenue
$538.40M
▲ 16% YoY
Diluted EPS
$0.79
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-19
Royalty Pharma plc (RPRX) Q2 2020 Earnings Call Transcript
Revenue
$510.93M
▲ 11.7% YoY
Diluted EPS
$0.09
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–31 of 31 webcasts
Key facts CIK 1802768 CUSIP G7709Q104 13F (30d) 10 filings 10 filers Visit website Investor relations